The Effects of Hypolipemic and Antidiabetic Treatment on Cytokines (MSF)
This study is not yet open for participant recruitment.
Verified July 2012 by Medical University of Silesia
Sponsor:
Medical University of Silesia
Information provided by (Responsible Party):
Bogusław Okopień, Medical University of Silesia
ClinicalTrials.gov Identifier:
NCT01101204
First received: April 7, 2010
Last updated: July 5, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study is planned to show whether combined hypolipemic and antidiabetic therapy with various daily dosages influence the fasting plasma glucose, insulin sensitivity and proinflammatory cytokines in diabetic and dyslipidemic subjects.
Condition | Intervention |
---|---|
Diabetes Dyslipidemia Inflammation Cytokines |
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science |
Official Title: | Effects of High and Low Doses of Metformin, Fenofibrate and Simvastatin, Administered Together and in Sequence With Lifestyle Intervention on Lipid Profile, Glucose Metabolism, Low-grade Inflammation and Hemostasis in Patient's Blood Plasma in Type 2 Diabetic Patients With Serious Mixed Dyslipidemia |
Resource links provided by NLM:
Further study details as provided by Medical University of Silesia:
Primary Outcome Measures:
- Antiinflammatory effects of combined antidiabetic and hypolipemic treatment [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
As inflammatory effects we measure the difference in serum concentration before and after the treatment of the following proinflammatory cytokines:
- Interleukin 1
- TNF alpha
- Interleukin 6
- Interleukin 10
- hsCRP
Secondary Outcome Measures:
- Insulin sensitivity [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]Assesed by HOMA (Homeostatic Model of Assessment)
- Coagulation parameters [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
Assessed using:
- Fibrinogen
- PAI-1
Estimated Enrollment: | 200 |
Study Start Date: | July 2012 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: M1000 S10 F100
metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Active Comparator: M1000 S10 F267
metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Active Comparator: M1000 S40 F100
metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Active Comparator: M1000 S40 F267
metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Active Comparator: M2500 S10 F100
metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Active Comparator: M2500 S10 F267
metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Active Comparator: M2500 S40 F267
metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Active Comparator: M2500 S40 F100
metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Placebo Comparator: Therapeutic Lifestyle Change
Only therapeutic lifestyle change
|
Drug: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
|
Eligibility
Ages Eligible for Study: | 35 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Age (35-64yr)
- Primary hyperlipidemia (Total cholesterol >200mg/dl, Triglycerides >150mg/dl)
- Type 2 Diabetes
- For women:
- Menopause (>12 months)
- Post hysterectomy
- Mechanical contraception
- Obtained informed consent
Exclusion Criteria:
- Secondary hyperlipidemia
- Morbid obesity (BMI>40kg/m2)
- Alcohol or drug abuse
- Acute or chronic inflammation
- Congestive Heart Failure (NYHA III or IV)
- Unstable Ischaemic Heart Disease
- Moderate or severe hypertension
- Cancer in less than 5 years
- Chronic kidney disease (stage III-V)
- Liver failure
- Oral contraception
- Not compliant patient
- Laboratory results:
- alanine transferase (>3xULN)
- creatine kinase (>5xULN)
- haemoglobin (<10/dl)
- PLT (<100G/l)
- WBC (<3,5G/l or >10G/l)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01101204
Contacts
Contact: Krzysztof Labuzek, MD, PhD | +48 32 252 39 02 | lbuldak@gmail.com |
Locations
Poland | |
Department of Clinical Pharmacology | Not yet recruiting |
Katowice, Poland, 40752 | |
Contact: Krzysztof Labuzek, MD, PhD +48 32 252 39 02 lbuldak@gmail.com | |
Sub-Investigator: Łukasz Bułdak, MD | |
Principal Investigator: Bogusław Okopień, MD, PhD | |
Sub-Investigator: Krzysztof Labuzek, MD, PhD |
Sponsors and Collaborators
Medical University of Silesia
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | Bogusław Okopień, MD PhD, Medical University of Silesia |
ClinicalTrials.gov Identifier: | NCT01101204 History of Changes |
Other Study ID Numbers: | MSF |
Study First Received: | April 7, 2010 |
Last Updated: | July 5, 2012 |
Health Authority: | Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products |
Additional relevant MeSH terms:
Inflammation Dyslipidemias Pathologic Processes Lipid Metabolism Disorders Metabolic Diseases Metformin Fenofibrate Simvastatin Hypoglycemic Agents Physiological Effects of Drugs |
Pharmacologic Actions Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Therapeutic Uses Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents Enzyme Inhibitors |
ClinicalTrials.gov processed this record on October 17, 2012